Michael Dykstra

Jun 4, 2024 | redjournal.org | Michael Dykstra |Patrick McLaughlin |Samuel N. Regan

For men with intermediate-risk prostate cancer treated with definitive therapy, the addition of androgen deprivation therapy (ADT) reduces the risk of distant metastasis and cancer-related mortality. However, the absolute benefit of ADT varies by baseline cancer risk. Estimates of prognosis have improved over time, and little is known about ADT decision making in the modern era.